Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

Company Overview - Lexicon Pharmaceuticals has appointed Mike Exton, Ph.D. as the new chief executive officer, succeeding Lonnel Coats who retired on July 7, 2024 [7] - Dr. Exton has extensive experience in the pharmaceutical industry, including 14 years at Novartis, where he led the global cardiometabolic therapeutic area [8] - Lexicon is focused on pioneering medicines that transform patients' lives, with a unique genomics target discovery platform called Genome5000™ [9] Leadership Changes - Concurrent with Dr. Exton's appointment, Jeff Wade has been named president and chief operating officer, having previously served as Lexicon's president and chief financial officer since October 2021 [4] - The board of directors expressed confidence in Dr. Exton's leadership capabilities, highlighting his successful track record in commercialization and strategic partnerships [3] Product Pipeline and Strategy - Lexicon has commercially launched INPEFA® (sotagliflozin) in the United States and has a pipeline of promising drug candidates in various stages of development, including neuropathic pain and diabetes [9] - The company aims to achieve operational objectives and secure necessary regulatory approvals for its drug candidates, which include LX9211 and LX9851 [10]